Skip to main content
Fig. 1 | Breast Cancer Research

Fig. 1

From: TBCRC 039: a phase II study of preoperative ruxolitinib with or without paclitaxel for triple-negative inflammatory breast cancer

Fig. 1

Clinical trial design, sample collection, and patient outcomes. A Scheme of clinical trial design and sample collection. Patients were eligible if their tumor was ER and PR ≤ 10% by immunohistochemistry and HER2-negative as defined by ASCO/CAP criteria. B Kaplan–Meier estimate of event-free survival (EFS) of all 23 patients. C Kaplan–Meier estimate of EFS according to neoadjuvant treatment. D Kaplan–Meier estimate of overall survival (OS) of all 23 patients; E Kaplan–Meier estimate of OS according to neoadjuvant treatment

Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us